SecBot SecBot

MIST drug pipeline

$0.3710
−7.0% 1-day · Nov 20
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±5.7%
1-day, median of 4 events
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially launched in the US (FDA approval December 2025, launch began February 2026). Also approved in China (September 2026).

CARDAMYST etripamil Updated Nov 13

What to watch

CARDAMYST is already approved and launched, so the next major catalyst is the Phase 3 ReVeRA-301 topline readout for AFib-RVR, which could expand the addressable market significantly. The company's Q3 2026 earnings today showed accelerating prescription growth (73% sequential revenue increase) but also a 30% cost-cutting plan, and the stock fell ~20% on the day. Watch for quarterly prescription and revenue trends as the key near-term value drivers.

Bull case
  • CARDAMYST is the first FDA-approved self-administered treatment for PSVT in 30 years, offering patients an at-home option that could reduce costly emergency room visits. The MedPage Today article from December 2025 notes it is a 'rapid-acting L-type calcium channel blocker' for at-home tachycardia conversion.
  • Q3 2026 results showed accelerating commercial traction: CARDAMYST revenue rose 73% sequentially, with steady prescription growth and new prescriber expansion, per the company's November 13, 2026 earnings release.
  • The company is pursuing a second, larger indication: a Phase 3 registrational trial (ReVeRA-301) for atrial fibrillation with rapid ventricular rate (AFib-RVR), which could significantly expand the addressable market. NMPA approval in China was also granted in September 2026.
Bear case
  • CARDAMYST faces competition from low-cost generic drugs (adenosine, verapamil, diltiazem) used in emergency settings for PSVT, which may limit pricing power and adoption. A Seeking Alpha analysis from August 2026 characterized Q2 revenue of just $559K on over 1,200 scripts as reflecting heavy discounting and minimal payer coverage.
  • The stock has collapsed from ~$2.95 before FDA approval in December 2025 to $0.52 today, a decline of over 80%, suggesting the market sees limited commercial potential. The company is cutting operating expenses by ~30% to preserve cash.
  • Institutional holders like Jane Street Group and Simplex Trading nearly exited their positions in Q3 2026, trimming by 77% and 99.3% respectively.

Past FDA events & how the stock moved

4 events
DateDrugEvent1 day5 days
Dec 15, 2025CARDAMYSTApproval−8.7%−14.1%
Dec 13, 2025CARDAMYSTNDA filed−2.7%−10.8%
Dec 13, 2025CARDAMYSTPDUFA decision−2.7%−10.8%
Dec 12, 2025CARDAMYSTApproval−20.5%−27.1%